Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681

Trial Profile

Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2012

At a glance

  • Drugs JNJ 37822681 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 31 Aug 2012 New trial record
    • 01 Aug 2012 Results published in the Journal of Psychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top